Literature DB >> 26858244

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Colin S Tan1,2, Kai Xiong Cheong3, Louis W Lim3, Shoun Tan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26858244     DOI： 10.1007/s00417-016-3284-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  6 in total

1.  Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.

Authors:  C S Tan; M C Chew; T H Lim
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

2.  Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Masaaki Saito; Tetsuju Sekiryu
Journal:  Am J Ophthalmol       Date:  2011-02-04       Impact factor: 5.258

3.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Alfredo Pece; Paolo Milani; Carla Monteleone; Costantino John Trombetta; Giuseppe De Crecchio; Giuseppe Fasolino; Domenica Matranga; Salvatore Cillino; Maria Vadalà
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-13       Impact factor: 3.117

4.  Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization.

Authors:  Vincenzo Isola; Alfredo Pece; Maurizio Battaglia Parodi
Journal:  Am J Ophthalmol       Date:  2006-10       Impact factor: 5.258

5.  Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy.

Authors:  Colin S Tan; Milton C Chew; Kai-Hung Lim; Tock-Han Lim
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

6.  Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy.

Authors:  Phil Young Lee; Ki Seok Kim; Won Ki Lee
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447
  6 in total
  1 in total

1.  EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study.

Authors:  Timothy Y Y Lai; Giovanni Staurenghi; Paolo Lanzetta; Frank G Holz; Shiao Hui Melissa Liew; Sabine Desset-Brethes; Harry Staines; Philip G Hykin
Journal:  Retina       Date:  2018-08       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.